Biopharma Mergers Surge in 2025: J&J's $14.6B Deal Leads
The biopharma industry has witnessed a surge in mergers and acquisitions, with several billion-dollar deals closing in recent months. The year's top deal by value is Johnson & Johnson's acquisition of Intra-Cellular Therapies, valued at a staggering $14.6 billion.
J&J's acquisition, finalized in January, has set the pace for the year. Meanwhile, Genmab's bid for Merus ranks as the third-largest deal of the year, valued at $8 billion. Merck's takeover of Verona Pharmaceuticals for $10 billion secures the second spot.
The third quarter saw a notable increase in biopharma acquisitions, with 21 deals closed, up from 16 in the second quarter and 15 in the first. Concentra Biosciences and Xoma Royalty emerged as the most acquisitive companies, each acquiring three struggling firms. Roche's purchase of 89bio is valued at $3.5 billion, while Pfizer's acquisition of Metsera totals $8.9 billion, including contingent value rights. Analysts anticipate a return to high-value dealmaking in the industry.
As the year progresses, the biopharma industry continues to witness significant consolidation, with several multibillion-dollar acquisitions reshaping the competitive landscape. Experts predict more high-value deals in the coming months.
Read also:
- User Data Analysis on Epic Games Store
- Rachel Reeves conducts a discussion with Scott Bessent and financial executives, focusing on investment matters
- Hyundai accelerates production plans: Introducing 7 new N models, aiming for a sales figure of 100,000 units by 2030.
- Yasa, an electric car engine producer, plans to broaden its operations.
